Personal tools

Offene Studien Rezidiv


AGO-Ovar 2.29

Atezolizumab in combination with Bevacizumab and Chemotherapy versus Bevacizumab and Chemotherapy in recurrent ovarian cancer

AGO-Ovar 2.31 / OREOStudie der Phase IIIb zur erneuten Erhaltungstherapie mit Olaparib bei Patientinnen mit epithelialem Ovarialkarzinom, die mit einem PARPi vorbehandelt wurden und auf eine wiederholte platinhaltige Chemotherapie ansprechen (OReO)
AGO-Ovar 2.32Trabectedin/PLD versus continuation of platinum-based chemotherapy in patients with disease stabilization and no symptom benefit under platinum-based chemotherapy for recurrent ovarian cancer.

An international, multi-centre, randomised phase II study to assess the efficacy of TAK228 as a single agent and in combination with intravenous weekly paclitaxel compared with weekly paclitaxel in women with advanced/recurrent clear cell, endometrioid and high grade serous carcinoma of the ovary

ENGOT-EN 5 / SIENDOA randomized phase III trial of maintenance with Selinexor / placebo after combination chemotherapy for patients with advanced or recurrent endometrial cancer

Prospective Study of HE4 serum Level in  Patients with First Relapsed Ovarian Cancer


Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 200kHz)
concomitant with weekly paclitaxel for the treatment of platinum-resistant ovarian cancer (PROC)

IOVANCE C-145-04

A Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-145) followed by IL-2 in Patients with Recurrent and/or Metastatic Cervical Carcinoma

PazoDoble II

Pazopanib versus Pazopanib plus Gemcitabin in Patientinnen mit rezidivierten oder metastasierten uterinen Leiomyosarkomen oder uterinen Carzinosarkomen